Skip to main content

Day: December 9, 2020

ArcelorMittal completes sale of ArcelorMittal USA to Cleveland-Cliffs

  9 December 2020, 14:15 CETArcelorMittal announces that the sale of ArcelorMittal USA to Cleveland-Cliffs for a combination of cash and stock has completed today.Under the terms of the sale, ArcelorMittal has received $505 million cash, 78 million shares of Cleveland-Cliffs common stock and non-voting preferred stock which is redeemable for approximately 58 million shares of Cleveland-Cliffs common stock or an equivalent amount in cash1. As agreed, Cleveland-Cliffs has assumed the liabilities of ArcelorMittal USA, including net liabilities of approximately $0.5 billion and pensions and other post-employment benefit liabilities (‘OPEB’)2.Commenting, Mr. Lakshmi Mittal, Chairman and CEO, ArcelorMittal, said:“I would like to thank everyone at ArcelorMittal USA for the important contribution they have made to the group. We wish you all the...

Continue reading

Hofseth Biocare ASA: APPROVAL AND PUBLICATION OF PROSPECTUS SUPPLEMENT FOLLOWING AGREEMENT WITH DKSH

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFULReference is made to the stock exchange announcements from Hofseth BioCare ASA (the “Company”) on 4 December 2020 regarding approval and publication of the Company’s prospectus dated 3 December 2020 (the “Prospectus”) and on 7 December 2020 regarding the commencement of the subscription period in a subsequent offering raising gross proceeds of up to approximately NOK 40 million (the “Subsequent Offering”).On 8 December 2020, e.g. following publication of the Prospectus, the Company published...

Continue reading

Biomerica’s InFoods® Irritable Bowel Syndrome Diagnostic-Guided Therapy Clinical Trial Nears Completion of Enrollment

Patient enrollment completion anticipated by the end of April 2021InFoods® Diagnostic-Guided Therapy is designed to address the $30 billion market for IBS treatmentTherapy seeks to identify patient-specific foods that trigger IBS symptoms and sufferingApproximately 45 million Americans suffer from IBS1IRVINE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today announced it is nearing completion of patient enrollment in the endpoint clinical trial for its InFoods® Irritable Bowel Syndrome (“IBS”) diagnostic-guided therapy (“DGT”). This double-blinded, randomized, controlled clinical trial is validating the Biomerica InFoods® IBS test to manage the debilitating pain and suffering of patients diagnosed with IBS. Utilizing an antibody guided blood test, the InFoods®...

Continue reading

Vera Bradley Announces Third Quarter Fiscal 2021 Results

Company posts third quarter GAAP EPS of $0.26 per diluted share, compared to $0.00 per diluted share last year, and non-GAAP EPS, excluding certain items, of $0.30 per diluted share, compared to $0.20 per diluted share last yearCompany delivers gross margin rate improvement and meaningful leverage on expenses for the quarterBalance sheet remains strong, with cash, cash equivalents, and investments of $77.3 millionFORT WAYNE, Ind., Dec. 09, 2020 (GLOBE NEWSWIRE) — Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced its financial results for the third quarter ended October 31, 2020.     Chief Executive Officer Rob Wallstrom noted, “Our quarterly earnings once again significantly exceeded last year’s performance as well as our expectations.   We expanded our gross margin rate primarily through sales of cotton masks and...

Continue reading

Sunstock, Inc. Provides Update on Gold, Silver Assets

SACRAMENTO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Sunstock, Inc. (OTC PINK: SSOK), involved in the buying, selling and distribution of precious metals, today announces an update on its gold and silver acquisitions during the final months of 2020.Through the months of October-December 2020, Sunstock grew its inventory by 4 ounces of gold bars and 4,500 ounces of silver for an aggregate investment of $161,297 for the noted period. The Company’s most recent acquisition of 300 ounces of Buffalo Silver Rounds was completed Dec. 2, 2020, adding to its existing inventory.Sunstock specializes in buying and selling gold, silver and rare coins to investors and customers. The Company monitors the precious metals market against the backdrop of the global economy to acquire assets at a pace and price conducive to its growth strategy. The...

Continue reading

German Companies Embrace Public Cloud Amid Pandemic, Boosting AWS and its Partner Ecosystem

FRANKFURT, Germany, Dec. 09, 2020 (GLOBE NEWSWIRE) — The new realities of business in the age of COVID-19 are driving more German enterprises to the cloud, giving Amazon Web Services and its partners greater opportunities to help these companies become more flexible and efficient, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.The 2020 ISG Provider Lens™ AWS Ecosystem Partners report for Germany finds the pandemic has created challenges that cloud-based resources and applications are particularly well equipped to address. Since lockdowns and business disruptions began early this year, the market penetration of cloud computing has accelerated from what was already one of the fastest growth rates of any IT trend in Germany.“German...

Continue reading

Deutsche Unternehmen schwenken in der Pandemie auf die Public Cloud um und stärken damit AWS und sein Partner-Ökosystem

FRANKFURT/MAIN, Dec. 09, 2020 (GLOBE NEWSWIRE) — Die neue Realität des Geschäftslebens im Zeitalter von COVID-19 lässt mehr und mehr deutsche Unternehmen auf die Cloud setzen. Dadurch steigen für Amazon Web Services (AWS) und ihre Partner die Chancen, diese Unternehmen auf ihrem Weg zu mehr Flexibilität und Effizienz zu unterstützen. Dies meldet eine neue, heute veröffentlichte Studie der Information Services Group (ISG) (Nasdaq: III). ISG ist ein führendes, globales Marktforschungs- und Beratungsunternehmen im Technologie-Segment.Der „ISG Provider Lens™ AWS Ecosystem Partners Report Germany 2020“ stellt fest, dass die Pandemie zu Herausforderungen geführt hat, für deren Bewältigung cloudbasierte Ressourcen und Anwendungen besonders gut geeignet sind. Mit dem Auftreten von Lockdowns und Störungen in den Geschäftsabläufen seit Anfang...

Continue reading

Cardtronics Confirms Receipt of Proposal from Apollo Global Management and Hudson Executive Capital to Acquire the Company

HOUSTON, Dec. 09, 2020 (GLOBE NEWSWIRE) — Cardtronics plc (“Cardtronics” or the “Company”) (Nasdaq: CATM) today confirmed that it has received a proposal from funds managed by affiliates of Apollo Global Management, Inc. and Hudson Executive Capital LP to acquire all of the outstanding shares of the Company for $31.00 per share in cash.Given his role as Founder & Managing Partner of Hudson Executive Capital LP, Douglas Braunstein has recused himself from any discussions that the Cardtronics Board of Directors has had regarding any transaction. The other members of the Cardtronics Board of Directors will review and assess the terms of the proposal.No specific timetable has been set and there can be no assurances that the review of this proposal will result in the consummation of any agreement or transaction. The Company does...

Continue reading

ERYTECH verkündet zuvor auf Jahrestagung der American Society of Hematology präsentierte positive Ergebnisse der Phase-II-Studie von Eryaspase bei akuter lymphoblastischer Leukämie

Webcast heute, Montag, den 7. Dezember,16:00 Uhr MEZ / 10:00 Uhr ETDie Studie bestätigt das Potenzial von Eryaspase als attraktive Behandlungsoption für ALL-Patienten mit Überempfindlichkeit gegenüber PEG-AsparaginaseLYON, Frankreich und CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq und Euronext: ERYP), ein biopharmazeutisches Unternehmen im Bereich der klinischen Forschung, das innovative Therapien entwickelt, bei denen Arzneimittelwirkstoffe in roten Blutkörperchen eingekapselt werden, gibt heute die Ergebnisse der von der NOPHO gesponserten Phase-II-Studie von Eryaspase bei Patienten mit akuter lymphoblastischer Leukämie (ALL) bekannt, die gestern von Dr. Line Stensig Lynggaard auf der 62. Jahrestagung der American Society of Hematology (ASH) präsentiert wurden. In dem heute stattfindenden Webcast...

Continue reading

ERYTECH annuncia i risultati positivi dello studio di Fase II su eryaspase per il trattamento della leucemia linfoblastica acuta, presentati in occasione del convegno annuale dell’American Society of Hematology

Il webcast è programmato per oggi, lunedì 7 dicembre,alle ore 16:00 CET/10:00 ETLo studio conferma il potenziale di eryaspase come opzione terapeutica interessante per i pazienti affetti da leucemia linfoblastica acuta (LLA) con ipersensibilità all’asparaginasi pegilata.LIONE, Francia e CAMBRIDGE, Mass., Dec. 09, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), un’azienda biofarmaceutica che svolge studi clinici e sviluppa terapie innovative con l’incapsulamento di principi attivi terapeutici nei globuli rossi, ha annunciato oggi i risultati dello studio di Fase II sponsorizzato da NOPHO di eryaspase in pazienti affetti da LLA, presentati ieri dalla Dott.ssa Line Stensig Lynggaard in occasione del 62oconvegno annuale dell’American Society of Hematology (ASH). Durante il webcast trasmesso oggi,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.